This article is for premium subscribers. Please sign up here for a tax-deductible subscription.
If you're a premium subscriber, sign in below.
A panel of experts discussed the current vaccine candidates and the likely timeline of having one that will provide immunity to people next year.
A growing number of prominent health leaders fear that President Donald Trump will legally autorize a vaccine before election day, running roughshod over the usual regulatory process.
So far, participation by minority volunteers in coronavirus trials has increased only slightly compared with the usually low levels in other clinical trials.
The Food and Drug Administration is weighing whether to resume a coronavirus vaccine trial that was halted when a volunteer suffered spinal cord damage as federal health officials launch an investigation.
The nation's top infectious disease expert says If a monitoring board gave the green light, vaccine manufacturers would be obligated to end their trials early and make the shots available.
Oxford University has signed an exclusive deal with AstraZeneca that gives the pharmaceutical giant sole rights with no guarantee of low prices.
The nonprofit will be testing a new drug developed by Pfizer and BioNTech that produced a strong immune response in early trials.
During the next two months, vaccine makers hope to recruit 60,000 Americans, including in Oregon, to roll up their sleeves to test two vaccines.
With millions of lives on the line, researchers have been working at an unprecedented pace to develop a COVID-19 vaccine.